WCLC2020: Pembrolizumab plus chemotherapy provided durable clinical benefit in patients with metastatic squamous NSCLC
In this MEDtalk Martin Reck gives his perspective on KEYNOTE-407, which revealed that combining pembrolizumab with chemo-therapy in patients with previously untreated metastatic squamous NSCLC improved OS, PFS, and PFS-2, increased ORR, and longer duration of response than placebo plus chemotherapy. The data support the combination of pembrolizumab and chemotherapy as a first-line treat-ment for metastatic squamous NSCLC in patients with PD-L1‒positive and PD-L1‒negative tumors.
